This project will identify resolution pathways that become dysregulated when rheumatoid arthritis is complicated by diabetes, hypertension or cardiovascular disease. It will evaluate the vascular and cardioprotective actions of resoloxins using animal models, human vascular organoids and patient-derived tissues.